


August 27, 2026



Toregem BioPharma Co., Ltd.
448-5 Kajii-cho, Kamigyo-ku, Kyoto, Japan
Hiroki Wada, President & CEO
info@toregem.co.jp

Toregem BioPharma Announces New Executive Leadership Structure to Support Clinical Advancement and Global Growth

Kyoto, Japan – August 27, 2026 - Toregem BioPharma Co., Ltd. (Head Office: Kyoto; President & CEO: Hiroki Wada; “the Company”) today announced that it would transition to a new executive leadership structure designed to support future business expansion and further enhance corporate value.

At the Extraordinary General Meeting of Shareholders and the subsequent Board of Directors meeting held recently, the Company resolved to implement the following changes to its executive leadership, effective August 27, 2026.

Under its previous leadership structure, Toregem advanced the research and development of TRG035, completed the Phase I clinical trial, was selected for the AMED “Drug Discovery Venture Ecosystem Enhancement Program,” secured financing and established a dedicated R&D framework, thereby laying a strong foundation for future business.

As the Company enters the commercialization and expansion phase, Toregem will accelerate initiatives including the Phase II clinical trial of TRG035, additional fundraising, domestic and international business partnerships and development of new pipelines leveraging its established R&D capabilities. To execute these priorities more effectively, the Company will adopt a leadership structure that clearly delineates functional expertise and responsibilities, enabling rapid and consistent decision-making.

Position	Name	Notes
President & CEO	Hiroki Wada	Newly appointed
Director & CSO	Muneaki Hashimoto	Newly appointed
Director & CFO	Taku Murayama	Newly appointed

The three co-founders – Honoka Kiso, Katsu Takahashi and Muneo Takatani – will step down from their roles as Directors as of the same date. They will continue to contribute to the Company’s development by leveraging their expertise, experience and networks in newly defined roles.

This transition enhances the Toregem’s management capabilities for the next stage of growth while preserving the scientific strengths and business foundation built since the Company’s establishment. Toregem remains committed to advancing the clinical development of TRG035, expanding its business, delivering new therapeutic options to patients and further strengthening corporate value.

【About Toregem BioPharma Co., Ltd.】

- Founded: May 12, 2020
- Location: 448-5 Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
- Representative: Hiroki Wada
- Business: Development of regenerative therapeutics for tooth loss
- Website: <https://toregem.co.jp/en/>